Claim · 2013-11 · event · Stated in source · Supported

Recursion's IPO prospectus (15 April 2021) states that the company was formed in Delaware as a limited liability company in November 2013 under the name Recursion Pharmaceuticals, LLC.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Recursion Pharmaceuticals → is stated to have been founded in → November 2013

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Recursion Pharmaceuticalsis stated to have been founded in ↓November 2013

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2013-11 · event Records dated 2013 →

Scope and limitsThe prospectus states a formation month as a limited liability company; it does not establish a founder roster, which other records cover.

The evidence 01

primary sourceSupports the claim

Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock

Recursion Pharmaceuticals, Inc. (filed with the US SEC) · 2021-04-15

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“We were formed in Delaware as a limited liability company in November 2013 under the name Recursion Pharmaceuticals, LLC. In September 2016, we converted to a Delaware corporation and subsequently changed our name to Recursion Pharmaceuticals, Inc.”

Location in source Prospectus summary, "Corporate Information"

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Recursion Pharmaceuticals, Inc. (filed with the US SEC)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 487039a60194b9c022cbf378210cd78655434c824bb3d7ae49f77ed721d01b4a). SEC EDGAR 424B4, accession 0001193125-21-119404, filed 2021-04-16; prospectus dated April 15, 2021; as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Recursion Pharmaceuticals, Inc. (filed with the US SEC), “Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock”, 2021-04-15.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (37 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. A cross-family machine check (2026-10-30, item A2) answered the record’s question blind from fresh retrievals and agreed with the record. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. A source states the organisation’s founding date or year, at the precision it gives. Neither legal incorporation nor a complete founder roster is implied.

Date. Month as stated by the prospectus; no day is given. The prospectus also dates a conversion to a Delaware corporation to September 2016.

Record ID aib-co-recursion-founding-stated